Enzalutamide extends OS compared to an standard antiandrogen in ENZAMET trial, but …

The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Does antiandrogen withdrawal work better in a subset of men on ADT?

A Japanese clinical research group has suggested that antiandrogen withdrawal  after combined androgen blockade may work best in men whose cancer is progressing rapidly after a long period on an LHRH agonist + antiandrogen therapy. … READ MORE …

Understanding what gynecomastia can look (and feel) like

An article in today’s New England Journal of Medicine discusses treatment-induced gynecomastia (swelling and soreness of the breasts) in men being treated with androgen receptor inhibitors (antiandrogens) for progressive prostate cancer. … READ MORE …

Tamoxifen in prevention/management of gynecomastia and related, antiandrogen-induced side effects

According to a new, systematic review of data from four independently conducted clinical trials, tamoxifen may be the most effective agent for the management of breast events induced by treatment with non-steroidal antiandrogens (e.g., bicalutamide) in men with prostate cancer. … READ MORE …

MDV3100 gets a proper scientific name

According to a media release issued by Medivation immediately prior to the annual meeting of the American Association for Cancer Research in Chicago (now wrapping up), the drug we have all known as MDV3100 for the past few years now has an approved “scientific” name: enzalutamide. … READ MORE …

Sexual orientation and impact of androgen deprivation therapy

An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …

High-dose bicalutamide as second-line hormone therapy in CRPC patients

Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …